150 related articles for article (PubMed ID: 30706231)
21. Prognostic impact of early ctDNA dynamics during chemotherapy of metastatic cancer.
Faaborg L; Andersen RF; Wen SW; Thomsen CB; Raunkilde L; Hansen TF; Jensen LH; Steffensen KD; Jakobsen A
Future Oncol; 2023 Nov; 19(35):2361-2367. PubMed ID: 37965794
[No Abstract] [Full Text] [Related]
22. Utilization of Circulating Tumor DNA in the Surveillance Setting.
Gibbs JN; Dale PS; Weatherall AL
Am Surg; 2023 Sep; 89(9):3799-3802. PubMed ID: 37407271
[TBL] [Abstract][Full Text] [Related]
23. Circulating DNA and frequency of colorectal cancer brain metastases in a presumed high-risk group.
Callesen LB; Boysen AK; Andersen RF; Dalby RB; Spindler KG
Sci Rep; 2023 Oct; 13(1):18574. PubMed ID: 37903871
[TBL] [Abstract][Full Text] [Related]
24. Strategic Insight into the Combination Therapies for Metastatic Colorectal Cancer.
Kano Y; Suenaga M; Uetake H
Curr Oncol; 2023 Jul; 30(7):6546-6558. PubMed ID: 37504340
[TBL] [Abstract][Full Text] [Related]
25. Bintrafusp alfa, an anti-PD-L1:TGF-β trap fusion protein, in patients with ctDNA-positive, liver-limited metastatic colorectal cancer.
Morris VK; Overman MJ; Lam M; Parseghian CM; Johnson B; Dasari A; Raghav K; Kee BK; Huey R; Wolff RA; Shen JP; Li J; Zorrilla I; Tzeng CD; Tran Cao HS; Chun YS; Newhook TE; Vauthey N; Duose D; Luthra R; Haymaker C; Kopetz S
Cancer Res Commun; 2022 Sep; 2(9):979-986. PubMed ID: 36382087
[TBL] [Abstract][Full Text] [Related]
26. Circulating Tumor DNA and Management of Colorectal Cancer.
Krell M; Llera B; Brown ZJ
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201448
[TBL] [Abstract][Full Text] [Related]
27. The potential of ctDNA in locoregional therapies for colorectal cancer.
Boeken T; Blons H; Dean C; Sapoval M; Pellerin O
Lancet Gastroenterol Hepatol; 2023 Dec; 8(12):1072-1073. PubMed ID: 37951236
[No Abstract] [Full Text] [Related]
28. Circulating tumour DNA in colorectal cancer management.
Cohen R; Platell CF; McCoy MJ; Meehan K; Fuller K
Br J Surg; 2023 Jun; 110(7):773-783. PubMed ID: 37190784
[TBL] [Abstract][Full Text] [Related]
29. The role of ctDNA in endometrial cancer: A tool for risk stratification and disease monitoring.
Blitzer GC; Zhao SG; Bradley KA; Hartenbach EM
Gynecol Oncol; 2023 Nov; 178():170-171. PubMed ID: 37648640
[No Abstract] [Full Text] [Related]
30. Failure is not final: ctDNA-guided rechallenge therapy in colorectal cancer.
Siravegna G; Bardelli A
Ann Oncol; 2019 Feb; 30(2):157-159. PubMed ID: 30475974
[No Abstract] [Full Text] [Related]
31. Utility of circulating tumor DNA in patients undergoing hepatectomy for colorectal liver metastases.
Cnockaert P; Muscari F; Maulat C
Hepatobiliary Surg Nutr; 2023 Oct; 12(5):736-739. PubMed ID: 37886203
[No Abstract] [Full Text] [Related]
32. Circulating Tumor DNA Is Capable of Monitoring the Therapeutic Response and Resistance in Advanced Colorectal Cancer Patients Undergoing Combined Target and Chemotherapy.
Cao H; Liu X; Chen Y; Yang P; Huang T; Song L; Xu R
Front Oncol; 2020; 10():466. PubMed ID: 32318348
[TBL] [Abstract][Full Text] [Related]
33. Genotyping of circulating tumor DNA in cholangiocarcinoma reveals diagnostic and prognostic information.
Ettrich TJ; Schwerdel D; Dolnik A; Beuter F; Blätte TJ; Schmidt SA; Stanescu-Siegmund N; Steinacker J; Marienfeld R; Kleger A; Bullinger L; Seufferlein T; Berger AW
Sci Rep; 2019 Sep; 9(1):13261. PubMed ID: 31519967
[TBL] [Abstract][Full Text] [Related]
34. Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA.
Kaseb AO; Sánchez NS; Sen S; Kelley RK; Tan B; Bocobo AG; Lim KH; Abdel-Wahab R; Uemura M; Pestana RC; Qiao W; Xiao L; Morris J; Amin HM; Hassan MM; Rashid A; Banks KC; Lanman RB; Talasaz A; Mills-Shaw KR; George B; Haque A; Raghav KPS; Wolff RA; Yao JC; Meric-Bernstam F; Ikeda S; Kurzrock R
Clin Cancer Res; 2019 Oct; 25(20):6107-6118. PubMed ID: 31363003
[TBL] [Abstract][Full Text] [Related]
35. Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Colorectal Cancer: Implications for Response and Resistance to Targeted Therapeutics.
Choi IS; Kato S; Fanta PT; Leichman L; Okamura R; Raymond VM; Lanman RB; Lippman SM; Kurzrock R
Mol Cancer Ther; 2019 Oct; 18(10):1852-1862. PubMed ID: 31320401
[TBL] [Abstract][Full Text] [Related]
36. Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer.
Reinert T; Henriksen TV; Christensen E; Sharma S; Salari R; Sethi H; Knudsen M; Nordentoft I; Wu HT; Tin AS; Heilskov Rasmussen M; Vang S; Shchegrova S; Frydendahl Boll Johansen A; Srinivasan R; Assaf Z; Balcioglu M; Olson A; Dashner S; Hafez D; Navarro S; Goel S; Rabinowitz M; Billings P; Sigurjonsson S; Dyrskjøt L; Swenerton R; Aleshin A; Laurberg S; Husted Madsen A; Kannerup AS; Stribolt K; Palmelund Krag S; Iversen LH; Gotschalck Sunesen K; Lin CJ; Zimmermann BG; Lindbjerg Andersen C
JAMA Oncol; 2019 Aug; 5(8):1124-1131. PubMed ID: 31070691
[TBL] [Abstract][Full Text] [Related]
37. Plasma HER2 (
Siravegna G; Sartore-Bianchi A; Nagy RJ; Raghav K; Odegaard JI; Lanman RB; Trusolino L; Marsoni S; Siena S; Bardelli A
Clin Cancer Res; 2019 May; 25(10):3046-3053. PubMed ID: 30808777
[TBL] [Abstract][Full Text] [Related]
38. Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodige-14 Trial.
Bidard FC; Kiavue N; Ychou M; Cabel L; Stern MH; Madic J; Saliou A; Rampanou A; Decraene C; Bouché O; Rivoire M; Ghiringhelli F; Francois E; Guimbaud R; Mineur L; Khemissa-Akouz F; Mazard T; Moussata D; Proudhon C; Pierga JY; Stanbury T; Thézenas S; Mariani P
Cells; 2019 May; 8(6):. PubMed ID: 31142037
[TBL] [Abstract][Full Text] [Related]
39. Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: Biomarker Analyses From LUME-Colon 1.
Lenz HJ; Argiles G; Yoshino T; Tejpar S; Ciardiello F; Braunger J; Salnikov AV; Gabrielyan O; Schmid R; Höfler J; Kitzing T; Van Cutsem E
Clin Colorectal Cancer; 2021 Mar; 20(1):84-95.e8. PubMed ID: 33041226
[TBL] [Abstract][Full Text] [Related]
40. The Level of Preoperative Plasma KRAS Mutations and CEA Predict Survival of Patients Undergoing Surgery for Colorectal Cancer Liver Metastases.
Polivka J; Windrichova J; Pesta M; Houfkova K; Rezackova H; Macanova T; Vycital O; Kucera R; Slouka D; Topolcan O
Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32867151
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
